Acute Bacterial Conjunctivitis Research Articles

Molecular identification of the bacterium acute conjunctivitis by the method of sequensing gen 16S rRNA

Conjunctivitis is the most common eye disease, characterized by contextual inflammation, which can be caused by bacteria. The diagnosis of conjunctivitis is established based various factors, including the patients’s medical history, onset of eye symptoms, non-ocular symptoms, previous disease history, family medical history, allergies, and physical examination of the eyes, which may include assessments of visual acuity and vision field. Some cases of conjunctivitis require laboratory examinations to confirm the diagnosis. These may include cytological examination with Giemsa staining, Chlamydia Diagnostic Test, Nucleic acid amplification tests (NAATs) or Polymerase chain reaction (PCR), and microbiological tests. Microbiological examination helps identify the bacteria responsible for conjunctivitis and aids in treatment by prescribing antibiotics to suppress the growth of the infecting bacteria. While identification tests are not routinely performed, researchers often seek to determine the specific type of bacteria causing conjunctivitis infections, which may require several laboratory tests. Bacterial virulence plays a significant role, with genetic mutations potentially leading to severe infections of varying severity. Virulence genes encode proteins that express pathogenic properties. The species responsible for conjunctivitis can be definitively identified definitively through microbiological examination, utilizing methods such as the 16S Ribosomal RNA Sequencing (rRNA) technique, known for its accuracy and speed. This study aims to analyze the results of rRNA sequencing in cases of acute bacterial conjunctivitis caused by 16S rRNA genotyping. The research employed an exploratory metholodolot, with the results analyzed using the The Basic Local Alignment Search Tool (BLAST) tracking program database on the National Center for Biotechnology Information (NCBI) website. The findings revealed that Sphingomonas paucimobilis encoded the 16S rRNA using Universal Primary 27 F and 1492 R, obtained in a sequence size of 1351bp. The isolate demonstrated similarities to Sphingomonas paucimobilis.

A Review: Pink Eye Outbreak in India

Conjunctivitis or ‘Pink Eye’ is the inflammation or infection of the Conjunctivitis, the membrane covering the white part of the inner eyelid. The Conjunctiva is the thin, clear, mucus membrane that covers the white of the eye and the inner eyelid. Viruses causes up to 80% of all cases acute Conjunctivitis. All broad- spectrum antibiotic eyedrops seen in general to be effective in treating bacterial Conjunctivitis. Acute bacterial Conjunctivitis is common in children, with more than 50% of conjunctivitis cases beings bacterial in origin as per the mentioned evidences the present Review was designed to study outbreak of pink eye in the years 2023 considering past 4 to 5 years consist in July 2023 conjunctivitis cases data in Gujrat [India]: 2.17 lac, Delhi NCR[India]:1032, Maharashtra [India]: 87.761 K, Lucknow [ Up-India]: 40 to 46 Daily. The diseases cause normally 7 to 10 days.

For people with acute bacterial conjunctivitis, what are the effects of topic antibiotics?

For people with acute bacterial conjunctivitis, what are the effects of topic antibiotics?

Clinical Characterization of Inpatients with Acute Conjunctivitis: A Retrospective Analysis by Natural Language Processing and Machine Learning

Background Acute bacterial conjunctivitis (ABC) is a relatively common medical condition caused by different pathogens. Although it rarely threatens vision, it is one of the most common conditions that cause red eyes and may be accompanied by discomfort and discharge. The study aimed to identify and characterize inpatients with ABC treated with topical antibiotics. Methods The EHRead® technology, based on natural language processing (NLP) and machine learning, was used to extract and analyze the clinical information in the electronic health records (EHRs) of antibiotic-treated patients with conjunctivitis and admitted to five hospitals in Spain between January 2014 and December 2018. Categorical variables were described by frequency, whereas numerical variables included the mean, standard deviation, median, and quartiles. Results From a source population of 2,071,812 adult patients who attended the participating hospitals in the study period, 11,110 patients diagnosed with acute conjunctivitis were identified. Six thousand five hundred eighty-three patients were treated with antibiotics, comprising the final study population. Microbiology was tested only on 12.1% of patients. Antibiotics, mainly tobramycin, and corticosteroids, mainly dexamethasone, were usually prescribed. NSAIDs were also used in about 50% of patients, always combined with antibiotics. Conclusions The present study provided a realistic representation of the hospital practice concerning managing patients with acute antibiotic-treated conjunctivitis. The diagnosis is usually based on the clinical ground, microbiology is rarely tested, few bacteria species are involved, and local antibiotics are frequently associated with corticosteroids and/or NSAIDs. Moreover, this study provided clinically relevant outcomes, based on new technology, that could be applied in clinical practice.

Safety and Efficacy of Black Tea Extract in the Treatment of Acute Bacterial Conjunctivitis: A Rabbit Model.

To determine the safety and efficacy of black tea extract in the treatment of bacterial conjunctivitis in a rabbit model and compare it with that of gatifloxacin drops. Black tea extract was tested in vitro on bacterial cultures of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Forty-two rabbit eyes were cultured with either MRSA (n=21) or P. aeruginosa (n=21) and further divided into a control group (n=5), a tea group (n=8) treated with black tea extract, and a gatifloxacin group (n=8) treated with 0.3% gatifloxacin eye drops. Conjunctival swabs were collected on the third and fifth days. The tea extract successfully inhibited the growth of both organisms at a concentration of 400 mg/mL. Rabbits in the treatment groups showed a reduction in the clinical index on day 2 (P<0.01), unlike the control group (P=0.1), for both organisms. Resolution of conjunctivitis was achieved on days 4 and 5 in the tea and gatifloxacin groups, respectively. On days 3 and 5, while the control group still showed considerable bacterial growth, the tea and gatifloxacin groups showed its inhibition. Tea extract has antimicrobial effects similar to those of gatifloxacin in a rabbit model of conjunctivitis.

Acute Bacterial Conjunctivitis in Pediatric Clinic: Causes and Management

Acute Bacterial Conjunctivitis in Pediatric Clinic: Causes and Management

Meta-analysis of the efficacy and safety of Gatifloxacin and Levofloxacin in the acute bacterial conjunctivitis

Meta-analysis of the efficacy and safety of Gatifloxacin and Levofloxacin in the acute bacterial conjunctivitis

Infection After Endoscopic Dacryocystorhinostomy: Incidence and Implications

Endoscopic dacryocystorhinostomy (EN-DCR) is an increasingly common procedure performed by otolaryngologists. While EN-DCR has a high rate of success at relieving blockage of the lacrimal system, little is known regarding associated postoperative infection (POI) rates and risk factors. The purpose of this study was to identify factors associated with the occurrence of postoperative orbital and rhinologic infection in a large cohort of patients undergoing EN-DCR. A retrospective review of 582 patients who underwent EN-DCR was performed. All patients received antibiotic prophylaxis as a single intraoperative intravenous administration and a ten-day postoperative oral course. Clinical and demographic information was reviewed, including the occurrence of acute orbital or rhinologic infection within 30 days of surgery. Multivariable analysis was performed to identify risk factors associated with POI. Fifteen of 582 patients (2.6%) developed POI following EN-DCR. The most common POI was acute rhinosinusitis (10/15, 66.7%), followed by acute dacryocystitis (2/15, 13.3%), preseptal cellulitis (2/15,13.3%), and acute bacterial conjunctivitis (1/15, 6.7%). The majority of patients (464/582, 79.7%) underwent concurrent endoscopic sinus surgery (ESS). In most cases (302/464, 65.1%), ESS was performed to address comorbid rhinosinusitis, whereas 7.8% (36/464) of patients underwent surgery to enhance surgical access to the lacrimal sac. Patients who underwent concurrent ESS were less likely to develop POI (OR: 0.17, CI: 0.04-0.80, p < 0.05). Evidence of mucopurulence at surgery increased the likelihood of POI (OR: 6.24, CI: 1.51-25.84, p < 0.05). Mucopurulence at the time of surgery significantly increased the risk of POI, whereas concurrent ESS, performed most commonly to address comorbid rhinosinusitis, significantly decreased the risk of POI. Awareness of risk factors for POI and appropriate surgical management of concurrent rhinosinusitis can lead to reduced infectious complications after EN-DCR.

Network pharmacology-based analysis: Fufang Xiongdan Diyanye—clinical response and mechanism of action in the treatment of acute bacterial conjunctivitis

Network pharmacology-based analysis: Fufang Xiongdan Diyanye—clinical response and mechanism of action in the treatment of acute bacterial conjunctivitis

COVID-19 and Telehealth: Prevention of Exposure in a Medically Complex Patient With a Mild Presentation

The novel coronavirus disease-2019 (COVID-19) was declared a pandemic by the World Health Organization on March 11, 2020. We discuss a less common presentation of COVID-19 in a patient where the use of telemedicine technology prevented the exposure of the healthcare team in an academic general pediatrics clinic. A medically complex 20-year-old male presented via virtual visit for unilateral eye redness and discharge. He received topical ophthalmic antibiotics for presumed acute bacterial conjunctivitis and was counseled on return precautions. Three days later, the patient developed shortness of breath, fever to 102.6°F, and chest pain. COVID-19 testing returned positive. Conjunctivitis is a presenting symptom in 32% of COVID-19 cases. Current evidence suggests that these patients may transmit their illness at the time of presentation. Using telehealth, we avoided exposure to a COVID-19–positive patient who would not have met criteria for testing or droplet precautions. Telehealth allows providers to triage patients, identifying those who need to be seen in person, thereby minimizing exposure. Transitioning toward virtual practice, particularly during a pandemic, prepares for the possibility of healthcare workers being quarantined but still able to provide care and minimizes exposure to asymptomatic patients or those with atypical symptoms.

A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis

To evaluate the efficacy and safety of a topical ophthalmic suspension combination of povidone-iodine 0.6% (PVP-I) and dexamethasone 0.1% (DEX) for infectious and inflammatory components of bacterial conjunctivitis. Randomized, double-masked, multicenter, phase 3 clinical trial. Subjects of all ages (those <3months had to be full-term) with a diagnosis of bacterial conjunctivitis were randomized 3:1:3 to either PVP-I/DEX, PVP-I alone, or placebo. The primary endpoint was clinical resolution in the study eye, and the key secondary efficacy endpoint was bacterial eradication, both at the day 5 visit. Adverse events (AEs) were documented at all visits. Overall, 753 subjects were randomized (intent-to-treat [ITT] population; PVP-I/DEX [n= 324]; PVP-I [n= 108]; placebo [n= 321]); mean and standard deviation (SD) age was 44.3 (22.9) years, and most were female (61.2%) and white (78.1%). In all treatment groups, mean treatment compliance was >98%. The modified ITT population for the efficacy analysis comprised 526 subjects. In the study eye at the day 5 visit, clinical resolution was achieved by 50.5% (111/220) subjects in the PVP-I/DEX group vs 42.8% (95/222) in the placebo group (P= .127), and bacterial eradication was achieved by 43.3% (94/217) and 46.8% (102/218), respectively (P= .500). Treatment-emergent AEs were experienced by 32.8% (106/323), 39.8% (43/108), and 19.0% (61/321) of subjects in the safety population treated with PVP-I/DEX, PVP-I, and placebo, respectively (most mild in severity). In this study, PVP-I/DEX did not demonstrate additional benefit in clinical efficacy compared with placebo in subjects with bacterial conjunctivitis.

Modern opportunities for the prevention and treatment of inflammatory eye diseases of an infectious nature in children

The development of inflammatory diseases of the cornea and conjunctiva, as well as the occurrence of infectious complications of intraocular surgery, are largely associated with the presence of saprophytic and pathogenic microflora in the conjunctival cavity. This circumstance is more characteristic of children. At the same time, the possibilities of antibacterial therapy of inflammatory eye diseases of bacterial and chlamydial etiology, as well as perioperative prophylaxis of infectious complications of intraocular surgical procedures in children, have significantly expanded today. The widespread use of fluoroquinolones has significantly improved the treatment of children with acute and chronic bacterial conjunctivitis, keratitis, blepharitis, meibomyitis, chalazion, as well as those with chronic conjunctivitis of chlamydial etiology. At the same time, levofloxacin fluoroquinolone of the 3rd generation, which is used in our country in the form of a 0.5% solution as eye drops Oftaquix (Santen, Finland), has demonstrated high efficacy for this purpose. The widespread introduction of the original 0.5% levofloxacin (Oftaquix), in the treatment regimen for children with inflammatory diseases of the cornea and conjunctiva, as well as for a perioperative prevention of infectious complications of surgical procedures involving them, is a promising way to solve the problem.

Dexamethasone Improves Ofloxacin Efficacy in Treating Acute Bacterial Conjunctivitis: Evidence from A Rabbit Model

Bacterial conjunctivitis represents the major part of infectious conjunctivitis and, although it generally shows a spontaneous resolution, antibiotics speed the elimination of bacteria from the conjunctiva thus limiting the duration of the disease. The addition of anti-inflammatory drugs may potentiate the effectiveness of antibiotics in eradicating bacterial conjunctivitis. Aim of the present study is to compare the efficacy of two different eye drops based on ofloxacin without or with dexamethasone against bacterial conjunctivitis induced by <i>Staphylococcus aureus</i> or Pseudomonas aeruginosa.

Bacteriological pattern and their correlation with complications in culture positive cases of acute bacterial conjunctivitis in a tertiary care hospital of upper Assam: A cross sectional study.

Acute conjunctivitis is inflammation of conjunctiva of less than 3 to 4 weeks duration, characterized by cellular infiltration and exudation. It may also result into corneal, lid or orbital involvement which may lead to various complications.A hospital based prospective study was conducted in Assam Medical College and Hospital with 110 culture proven acute bacterial conjunctivitis cases. Primary objective was to evaluate the bacteriological pattern and secondary objectives were to evaluate seasonal variation, association of different organisms with various complications and antibiotic sensitivity pattern of the isolates.Maximum frequency of bacterial conjunctivitis observed from May to September. SA was the predominant organism isolated throughout the year (32.1%). Commonest single organism isolates were SE (26.1%) and SA (21.6%). True membrane formation was significantly associated with CD (P < .05), whereas pseudo-membrane formation was associated with SA and STBH isolation (P < .05). Isolation of SE, SA, and PA was associated with corneal involvement (P < .05). Lid involvement was seen with SA and Diphtheroid, whereas SP isolation was associated with concomitant dacryocystitis (P < .05). All the major organisms were (SE, SA, D, STBH, SP) highly sensitive to amino-glycosides, cephalosporins, chloromphenicol, vancomycin and linezolid, whereas high level of resistance was seen towards fluroquinolones (ciprofloxacin and moxifloxacin).All acute bacterial conjunctivitis cases don’t require antibiotic therapy. In case if required, periodical culture and sensitivity may guide initial pre-emptive antibiotic therapy. Further choice of antibiotic should be govern by culture and sensitivity status.

Comparison of Tobramycin and Moxifloxacin eye drops in acute bacterial conjunctivitis: An open label randomized controlled institutional study from Kolkata

Comparison of Tobramycin and Moxifloxacin eye drops in acute bacterial conjunctivitis: An open label randomized controlled institutional study from Kolkata

Treating with besifloxacin for acute bacterial conjunctivitis: a Meta-analysis.

To evaluate the relative efficacy and safety of besifloxacin for treatment of acute bacterial conjunctivitis. A comprehensive search in PubMed, EMBASE Web of Science, Cochrane Central Database and CNKI was undertaken for randomized controlled trials (RCTs) comparing besifloxacin with other treatments or placebo. The primary outcome measures were clinical resolution, rates of bacterial eradication, individual clinical outcomes, cure rates, and bacterial eradication rates of different kinds of pathogens. Safety outcomes were the number of adverse effects (AEs). The final search was performed on August 2018. Six RCTs were included. Four studies compared the efficacy and safety of besifloxacin with placebo, 1 study compared besifloxacin with moxifloxacin, and 1 study compared besifloxacin with gatifloxacin. A total of 2780 patients met the inclusion criteria. Besifloxacin presented higher efficacy and safety than did placebo in clinical resolution, rates of bacterial eradication, individual clinical outcomes, cure rates, bacterial eradication rates of different kinds of pathogens and the number of AEs. There was no significant difference between besifloxacin and moxifloxacin or gatifloxacin in the comparison items mentioned above. Besifloxacin is highly effective and safe for treatment of acute bacterial conjunctivitis. Further comparative trials regarding the effect of besifloxacin for treatment of acute bacterial conjunctivitis will aid in treatment decisions.

Primary meningococcal conjunctivitis: Summary of evidence for the clinical and public health management of cases and close contacts

Neisseria meningitidis is a rare cause of acute bacterial conjunctivitis but can progress to invasive meningococcal disease (IMD) in the case and their close contacts. There is, however, a lack of consensus on the clinical and public health management of primary meningococcal conjunctivitis (PMC). We searched Ovid MEDLINE via PubMed, EMBASE and NHS evidence (up to June 2019) for all publications relating to meningococcal conjunctivitis to provide an evidence-base for developing guidelines for the management of PMC cases and their close contacts. The review identified a 10-29% risk of IMD among PMC cases within two days of onset of eye infection (range: 3h to 4 days). In one study, the risk of IMD in PMC cases treated with systemic antibiotics was 19 times lower than topical antibiotics alone (p = 0.001). IMD among close contacts of PMC cases is uncommon but potentially fatal. Whether meningococcal vaccination for PMC cases or close contacts provides any additional benefit is unclear. Systemic antibiotic treatment significantly reduces the risk of invasive disease in PMC cases, while antibiotic chemoprophylaxis for close contacts will reduce their risk of secondary IMD. These findings need to be highlighted in relevant clinical and public health guidelines.

Study of organisms isolation from acute bacterial conjunctivitis cases

Introduction: Conjunctivitis is an inflammation of the outermost layer of the white part of the eye and the inner surface of the eyelid. Conjunctivitis is a global economic burden due to its common occurrence, contagiousness and potentially debilitating morbidities. The bulk of conjunctivitis related costs include consultation, supportive care, drugs prescription, diagnostic tests and productivity loses associated with time away from work or school. Viral etiology was the main reason for most of the outbreaks. Conjunctivitis is one of the most common condition of the eye that affects all ages, social strata and occurs worldwide. Acute conjunctivitis has a symptoms of less than 3 to 4 weeks of duration. Some reports indicate that 50-75% of acute conjunctivitis are caused due to the bacteria. In adults Staphylococcus, S. pneumoniae and H. influenza are the common pathogens causing bacterial conjunctivitis. Materials and Methods: Total 70 eyes of 52 patients of diagnosed acute conjunctivitis were examined at our institute from April 2018 to January 2019. This is prospective observational study with evaluation of demographic factors, associated comorbid conditions and finding causative organism i.e. bacteria and /or fungus by gram staining, KOH mounting and culture sensitivity. Results: In our study acute conjunctivitis was commonly seen in males than females and in age group of 18-45. It was commonly seen in patients of low socioeconomic status. Predominantly right eye involvement was observed. 16 cases showed positive results for Gram staining. KOH test was negative in all cases. S. aureus was the commonest organism identified on culture and sensitivity. S. aureus and S. pneumonae were equally isolated in patients on chronic steroid use. Conclusion: Bacterial conjunctivitis is more common i.e. 30.76 % than fungal in our study. No fungal organism was detected in our study. S. aureus, S. pneumonae, H. influenzae and S. epididymis were most common bacterias seen in our s

Establishment of rapid diagnostic method for the identification of Staphylococcus aureus in bacterial conjunctivitis

Staphylococcus aureus is the most frequent cause of conjunctivitis and may lead to severe visual impairment. However, the tools available for the diagnosis, such as bacterial culture and cytology, are often inadequate. Therefore, the goal of the present work was to establish a rapid detection method for S. aureus in the secretions of the conjunctival sac to provide a basis for the early diagnosis of acute bacterial conjunctivitis. The study included 32 patients with acute bacterial conjunctivitis, 30 patients with viral conjunctivitis, and 28 control subjects. Extracted DNA was analyzed by conventional PCR and RT-PCR using primers specific for S. aureus DNA and two antibiotic resistance genes, mecA and femB. By this technique, S. aureus was found in 37.5% of patients with bacterial conjunctivitis, 20% of patients with viral conjunctivitis, and in 7.1% normal control subjects. Except for the control group in which the femB gene was not found, in most other cases S. aureus carried mecA and femB genes. The developed molecular biology approach is faster and more sensitive than the methods requiring bacterial cultures and is uniquely suited for the detection of an S. aureus infection in the eye.

The efficacy and safety of besifloxacin for acute bacterial conjunctivitis: a Meta-analysis.

To evaluate the relative efficacy and safety of besifloxacin for treatment of acute bacterial conjunctivitis. A comprehensive search in PubMed, EMBASE Web of Science, Cochrane Central Database and CNKI was undertaken for randomized controlled trials (RCTs) comparing besifloxacin with other treatments or placebo. The primary outcome measures were clinical resolution, rates of bacterial eradication, individual clinical outcomes, cure rates, and bacterial eradication rates of different kinds of pathogens. Safety outcomes were the number of adverse effects (AEs). The final search was performed on August 2018. Eight RCTs were included. Five studies compared the efficacy and safety of besifloxacin with placebo, 2 studies compared besifloxacin with moxifloxacin, and 1 study compared besifloxacin with gatifloxacin. A total of 3105 patients met the inclusion criteria. Besifloxacin presented higher efficacy and safety than did placebo in clinical resolution, rates of bacterial eradication, individual clinical outcomes, cure rates, bacterial eradication rates of different kinds of pathogens and the number of AEs. There was no significant difference between besifloxacin and moxifloxacin or gatifloxacin in the comparison items mentioned above. Besifloxacin is highly effective and safe for treatment of acute bacterial conjunctivitis. Further comparative trials regarding the effect of besifloxacin for treatment of acute bacterial conjunctivitis will aid in treatment decisions.